Oncofertility: combination of ovarian stimulation with subsequent ovarian tissue extraction on the day of oocyte retrieval

Reproductive Biology and Endocrinology

Thomas Hildebrandt²  Matthias W Beckmann²  Kerstin U Amann³  David L Wachter³  Inge Hoffmann²  Andreas Mueller¹  Laura Lotz²  Ralf Dittrich² 

[1] Department of Obstetrics and Gynecology, Karlsruhe Hospital, Moltkestrasse 90, 76133, Karlsruhe, Germany;Department of Obstetrics and Gynecology, Erlangen University Hospital, Universitätsstrasse 21-23, 91054, Erlangen, Germany;Department of Pathology, Erlangen University Hospital, Krankenhausstrasse 8-10, 91054, Erlangen, Germany

关键词: Ovarian tissue cryopreservation;    Oocyte cryopreservation;    IVF;    Ovarian stimulation;    Ovarian tissue;    Fertility preservation;   

Others  :  812505
DOI  :  10.1186/1477-7827-11-19

 received in 2012-11-05, accepted in 2013-02-19,  发布年份 2013

【 摘 要 】

Background

New anticancer treatments have increased survival rates for cancer patients, but often at the cost of sterility. Several strategies are currently available for preserving fertility. However, the chances of achieving a pregnancy with one technique are still limited. A combination of methods is therefore recommended in order to maximize women’s chances of future fertility. In this retrospective study, ovarian stimulation with subsequent ovarian tissue extraction on the day of oocyte retrieval were combined and the quality of the ovarian tissue, the numbers and quality of oocytes, time requirements, and the safety of the strategy were examined.

Methods

Fourteen female patients suffering from malignant diseases underwent one in vitro fertilization cycle. Different stimulation protocols were used, depending on the menstrual cycle. Transvaginal oocyte retrieval was scheduled 34–36 h after human chorionic gonadotropin administration. Immediately afterwards, ovarian tissue was extracted laparoscopically.

Results

A mean of 10 oocytes were retrieved per patient, and 67% of the oocytes were successfully fertilized using intracytoplasmic sperm injection. No periprocedural complications and no complications leading to postponement of the start of chemotherapy occurred. The ovarian tissues were of good quality, with a normal age-related follicular distribution and without carcinoma cell invasion.

Conclusions

An approach using ovarian stimulation first, followed by laparoscopic collection of ovarian tissue, is a useful strategy for increasing the efficacy of fertility preservation techniques. The ovarian tissue is not affected by prior ovarian stimulation.

【 授权许可】

   
2013 Dittrich et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Dittrich R, Maltaris T, Hoffmann I, Oppelt PG, Beckmann MW, Mueller A: Fertility preservation in cancer patients. Minerva Ginecol 2010, 62:63-80.
• [2]Lawrenz B, Jauckus J, Kupka M, Strowitzki T, Wolff M: Fertility preservation in >1,000 patients: patient’s characteristics, spectrum, efficacy and risks of applied preservation techniques. Arch Gynecol Obstet 2011, 283:651-656.
• [3]Rodriguez-Wallberg KA, Oktay K: Options on fertility preservation in female cancer patients. Cancer Treat Rev 2012, 38:354-361.
• [4]Maltaris T, Beckmann MW, Dittrich R: Fertility preservation for young female cancer patients. In Vivo 2009, 23:123-130.
• [5]Huser M, Zakova J, Smardova L, Crha I, Janku P, Hudecek R, Ventruba P: Combination of fertility preservation strategies in young women with recently diagnosed cancer. Eur J Gynaecol Oncol 2012, 33:42-50.
• [6]Del Gadillo JCB, Siebzehnrübl E, Dittrich R, Wildt L, Lang N: Comparison of GnRH agonists and antagonists in unselected IVF/ICSI patients treated with different controlled ovarian hyperstimulation protocols: a matched study. Eur J Obstet Gynecol Reprod Biol 2002, 102:179-183.
• [7]Bodri D, Vernaeve V, Guillén JJ, Vidal R, Figueras F, Coll O: Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial. Hum Reprod 2006, 21:2246-2251.
• [8]von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, Strowitzki T: Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril 2009, 92:1360-1365.
• [9]Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, Bang H: Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006, 91:3885-3890.
• [10]Azim AA, Costantini-Ferrando M, Oktay K: Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008, 26:2630-2635.
• [11]Dittrich R, Maltaris T: A simple freezing protocol for the use of an open freezing system for cryopreservation of ovarian tissue. Cryobiology 2006, 52:166.
• [12]Ata B, Chian RC, Tan SL: Cryopreservation of oocytes and embryos for fertility preservation for female cancer patients. Best Pract Res Clin Obstet Gynaecol 2010, 24:101-112.
• [13]Sonmezer M, Oktay K: Fertility preservation in female patients. Hum Reprod Update 2004, 10:251-266.
• [14]Noyes N, Knopman JM, Melzer K, Fino ME, Friedman B, Westphal LM: Oocyte cryopreservation as a fertility preservation measure for cancer patients. Reprod Biomed Online 2011, 23:323-333.
• [15]Yoon TK, Lee DR, Cha SK, Chung HM, Lee WS, Cha KY: Survival rate of human oocytes and pregnancy outcome after vitrification using slush nitrogen in assisted reproductive technologies. Fertil Steril 2007, 88:952-956.
• [16]von Wolff M, Donnez J, Hovatta O, Keros V, Maltaris T, Montag M, Salle B, Sonmezer M, Andersen CY: Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy—a technique in its infancy but already successful in fertility preservation. Eur J Cancer 2009, 45:1547-1553.
• [17]Rosendahl M, Greve T, Andersen CY: The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. J Assist Reprod Genet 2013, 30:11-24.
• [18]Donnez J, Jadoul P, Pirard C, Hutchings G, Demylle D, Squifflet J, Smitz J, Dolmans MM: Live birth after transplantation of frozen–thawed ovarian tissue after bilateral oophorectomy for benign disease. Fertil Steril 2012, 98:720-725.
• [19]Silber S, Kagawa N, Kuwayama M, Gosden R: Duration of fertility after fresh and frozen ovary transplantation. Fertil Steril 2010, 94:2191-2196.
• [20]Revel A, Laufer N, Ben Meir A, Lebovich M, Mitrani E: Micro-organ ovarian transplantation enables pregnancy: a case report. Hum Reprod 2011, 26:1097-1103.
• [21]Dittrich R, Lotz L, Keck G, Hoffmann I, Mueller A, Beckmann MW, van der Ven H, Montag M: Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation. Fertil Steril 2012, 97:387-390.
• [22]Huober-Zeeb C, Lawrenz B, Popovici RM, Strowitzki T, Germeyer A, Stute P, von Wolff M: Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. Fertil Steril 2011, 95:342-344.
• [23]Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, Kuperwasser C: Systemic stromal effects of estrogen promote the growth of estrogen receptor–negative cancers. Cancer Res 2007, 67:2062-2071.
• [24]Checa Vizcaíno MA, Corchado AR, Sastre I, Cuadri ME, Comadran MG, Brassesco M, Carreras R: The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. Reprod Biomed Online 2012, 24:606-610.
• [25]Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z: Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003, 18:90-95.
• [26]Oktay K, Türkçüoğlu I, Rodriguez-Wallberg KA: GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 2010, 20:783-788.
• [27]Humaidan P: Agonist trigger: what is the best approach? Agonist trigger and low dose hCG. Fertil Steril 2012, 97:529-530.
• [28]Dolmans MM, Demylle D, Martinez-Madrid B, Donnez J: Efficacy of in vitro fertilization after chemotherapy. Fertil Steril 2005, 83:897-901.
• [29]Meirow D, Epstein M, Lewis H, Nugent D, Gosden RG: Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod 2001, 16:632-637.
• [30]Huang JYJ, Tulandi T, Holzer H, Tan SL, Chian RC: Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation. Fertil Steril 2008, 89:567-572.
• [31]Fasano G, Moffa F, Dechène J, Englert Y, Demeestere I: Vitrification of in vitro matured oocytes collected from antral follicles at the time of ovarian tissue cryopreservation. Reprod Biol Endocrinol 2011, 9:150. BioMed Central Full Text
• [32]Suikkari AM: In-vitro maturation: its role in fertility treatment. Curr Opin Obstet Gynecol 2008, 20:242-248.
• [33]Badawy A, Elnashar A, El-Ashry M, Shahat M: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009, 91:694-697.
• [34]von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B: Fertility preservation in women—a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet 2011, 284:427-435.